initial public offerings (IPOs) trading on American exchanges
Showing posts with label Israeli IPOs. Show all posts
Showing posts with label Israeli IPOs. Show all posts

Tuesday, July 27, 2021

ironSource (IS) began trading on the NYSE on Tue 29 June 21

ironSource is an Israeli software company backed by Carmel Ventures, a Viola Group affiliate, as well as CVC Capital Partners. The company focuses on developing technologies for app monetization and distribution, with its core products focused on the app economy.  
  • Number of employees: 1000+
  • Number of locations: 12
  • Founder: Tomer Bar-Zeev
  • Headquarters: Israel
  • Founded: 2009, Tel Aviv-Yafo, Israel
  • Subsidiaries: Luna Labs Limited, Soomla Inc., Upopa Games, AfterDownload Ltd.
  • CEO Tomer Bar-zeev
  • is.com


CEO Tomer Bar-zeev

Founded in 2009, IronSource is based in Tel Aviv, with additional offices in San Francisco, New York, London, and other locations in China, India and South Korea. Originally a downloads optimization software developer, IronSource shifted its focus to rewarded ads following a series of acquisitions between 2013 and 2016. The company has raised $105 million to date.

Aside from company employees, IronSource’s shareholders include Israel-based Viola Ventures, Los-Angeles-based Saban Ventures, the venture arm of the Saban Group, Allied Holdings, the controlling shareholder of Champion Motors Israel, and Arik Czerniak, co-founder of app monetization company Supersonic, which was acquired by IronSource in 2015.


Thursday, January 28, 2021

NeoGames (NGMS) began trading on the Nasdaq on Thur 19 Nov 20

NeoGames S.A. provides a suite of iLottery technology solutions worldwide.
The company also offers software development and platforms sub-licensing services; and regulation and compliance, payment processing, risk management, player relationship management, and player value optimization services. 
  • Headquartered in Tel Aviv, Israel.
NeoGames priced 4.8 mln share IPO at $17.00 per share, above the expected range of $14-16
Opened at $21.15


Thursday, September 17, 2020

JFrog (FROG) began trading on the Nasdaq on Wed 16 Sept 20

JFrog Ltd. provides DevOps platform to achieve continuous software release management platform enabling organizations to deliver software updates across any system. Its platform acts as bridge between software development and deployment, which enable organizations to build and release software faster. JFrog’s DevOps platform is available as open-source, self-managed, and SaaS services on AWS, Microsoft Azure, and Google Cloud. The company serves technology, financial services, retail, healthcare, and telecommunications organizations.
  • Sector(s): Technology
  • Industry: Software—Application
  • Founded in 2008 in Israel
  • CEO Shlomi Ben Haim
  • HQ: Sunnyvale, California
  • http://www.jfrog.com
Priced 11.6 mln share IPO at $44.00 per share, above the expected range of $33-37
Closed +47% to $64.79, putting the market value at $6.6 billion. The company raised $352 million.






JFrog focuses on a growing niche called developer operations, or DevOps, which aims to streamline software development and management within organizations. 

The company's platform powers what it calls continuous delivery of software updates, helping to get new software versions to end customers more quickly and reliably.

The company says that covid-19 has increased the urgency of fast, reliable software updates -- and demand for its platform. 

"Every company is a software company today ... that is evident and clear," JFrog Chief Technology Officer Yoav Landman said. "You’ll be eaten by your competition if you can't release software versions fast enough." 

Friday, May 8, 2020

Ayala Pharmaceuticals (AYLA) began trading on the Nasdaq on Fri 8 May 2020

Ayala Pharmaceuticals, a Phase 2 biotech developing in-licensed Notch inhibitors for aggressive cancers, raised $55 million by offering 3.7 million shares at $15, the midpoint of the $14 to $16 range.
The biotech raised 10% more than expected; it originally filed to offer 3.3 million shares.


Rehovot, Israel-based Ayala was founded to to develop treatments for various cancers:
  • Recurrent/Metastatic Adenoid Cystic Carcinoma
  • Triple Negative Breast Cancer
  • Acute lymphoblastic leukemia
  • Desmoid, soft tissue tumors
A brief overview video of adenoid cystic carcinoma.

Management is headed by Chief Executive Officer Roni Mamluk, Ph.D., who has been with the firm since 2017 and was previously CEO at biopharmaceutical firm Chiasma and head of preclinical development of an oncology product at Adnexus Therapeutics.

Tuesday, May 5, 2020

Ayala Pharmaceuticals (AYLA) sets IPO terms

Ayala Pharmaceuticals (AYLA) has filed an updated preliminary prospectus for its IPO of ~3.3M common shares at $14 - 16 per share.
Underwriters' over-allotment will be up to an additional 500K shares.

The Rehovet, Israel-based biopharmaceutical outfit develops treatments for rare and aggressive cancers by leveraging its bioinformatics platform and next-gen sequencing.

https://www.ayalapharma.com/

Thursday, June 13, 2019

Fiverr (FVRR) began trading on the NYSE on Thur 13 June 2019

 ticker: FVRR
  • Sector: Communication Services
  • Industry: Internet Content & Information
  • Full Time Employees: 421
  • Founded in 2010 
  • Headquartered in Tel Aviv, Israel.
  • http://www.fiverr.com
Fiverr priced 5.26 mln share IPO at $21.00, above the expected $18.00-20.00 range
Opened for trading at $26




Sunday, June 9, 2019

Online insurer Lemonade seeking New York IPO

Firm founded by Israeli entrepreneurs Shai Wininger and Daniel Schreiber will seek to raise more than $500 million to expand operations
  • By replacing brokers and bureaucracy with bots and machine learning, Lemonade promises zero paperwork and instant everything. And as a Certified B-Corp, where underwriting profits go to nonprofits, Lemonade is remaking insurance as a social good, rather than a necessary evil.
  • Founded date 2015
  • www.lemonade.com
Lemonade co-founder Shai Wininger at his office in Tel Aviv on December 20, 2017 

Daniel Schreiber


management


New York-based Lemonade Insurance Company, founded by Israeli entrepreneurs Shai Wininger and Daniel Schreiber, who seek to revolutionize the way homes are insured, are planning to hold an initial public offering of shares on a New York exchange, Calcalist reported without saying where it got the information.

The firm is seeking to raise more than half a billion dollars, at a market valuation of $2 billion, the financial website reported Tuesday.

The share issue, if successful, would make the share sale one of the most highly valued IPOs by an Israeli-linked firm, Calcalist said. Mobileye, founded by Israeli entrepreneurs Amnon Shashua and Ziv Aviram, holds the record today, having sold shares in 2014 on the New York Stock Exchange at a valuation of $5.3 billion, Calcalist said. Mobileye was later acquired in 2017 by Intel Corp. for a whopping $15.3 billion.

Wednesday, April 10, 2019

Tufin (TUFN) prices IPO at $14 a share

Israeli cybersecurity company Tufin Software Technologies Ltd. priced shares at $14 in its initial public offering Wednesday evening, setting up the Israeli cybersecurity company for a Thursday trading debut. Tufin announced that it will sell 7.7 million shares at the top of its proposed IPO range, to bring in at least $107.8 million at an initial valuation of about $454 million. Tufin, which sells software focused on security policy and implementation, reported a loss of $4.3 million on revenue of $85 million last year, when sales grew more than 30%, according to filings with the Securities and Exchange Commission. Underwriters, led by JP Morgan, Barclays and Jefferies, have access to an additional 1.16 million shares if needed. Shares are expected to begin trading on the New York Stock Exchange on Thursday morning under the ticker symbol TUFN.



Tufin helps security managers automate changes to their networks while maintaining compliance with industry regulations and without introducing vulnerabilities. The company claims 2,000 enterprise customers in over 70 countries and it was co-founded by Kitov in 2005.

The company opened an office near Post Office Square in Boston in 2017. At that time, Kitov relocated to Boston from Israel and joined a team of 20 employees. In Boston, Tufin currently has a portion of the marketing and general administrative teams, as noted in the regulatory filing. The company, which also leases an office in Akron, Ohio, had a total of 119 employees in the U.S. as of December last year.

Tufin has raised a total of $30 million, according to Crunchbase. The company posted revenues of $64.5 million in 2017 and $85 million in 2018. In those years, Tufin also reported a net loss of $2.8 million and $4.3 million, respectively. In the filing, Tufin noted that its accumulated deficit as of December was $40.3 million.

In its upcoming IPO, Tufin is represented by White & Case. The company’s principal executive office is located in Ramat-Gan, a city with around 160,000 residents just east of Tel-Aviv, Israel.

Saturday, December 9, 2017

=ForeScout Technologies (FSCT) started trading on the Nasdaq on 27 October 2017

Software company; 17-year-old cybersecurity company

  • CEO: Michael DeCesare
  • Headquarters: Cupertino, CA
  • The company was founded in Israel in 2000 by chairman Hezy Yeshurun, together with Doron Shikmoni, CTO Oded Comay, chief architect Dror Comay, and Noga Alon. ForeScout moved its headquarters to California but maintains its development center in Tel Aviv.
  • forescout.com
  • 5.28 million shares at $22/sh raised $116 million; company valued of $816 million.
  • ForeScout's shareholders include UK firm Amadeus Capital with a 19.6% stake, US fund Accel (15.2%), Meritech (13.4%), and Wellington Management (7.7%). 





Description

ForeScout Technologies, Inc. is a United States-based provider of automated security control solutions. The Company transforms security through visibility. It offers enterprises and government organizations the ability to see devices, including non-traditional devices, the instant they connect to the network. It allows the user to control these devices and orchestrate information sharing and operation among disparate security tools to accelerate incident response. Its products include CounterACT Platform, CounterACT Models, Extended Integration Modules, Open Integration Module and Other Products. Its solutions integrate with network, security, mobility and information technology (IT) management products to automate workflows. The Company's solutions include Network Access Control; Endpoint Compliance; Bring Your Own Device (BYOD) & Mobile Security for Enterprise; Vulnerability Management, Policy and Solutions, and Advanced Network Threat Prevention and Cyber Defense Solutions.

Key stats and ratios

Q2 (Jun '17)2016
Net profit margin-49.94%-44.82%
Operating margin-48.80%-42.82%
EBITD margin--39.88%
Return on average assets-63.89%-44.21%
Return on average equity--
Employees800

Thursday, March 26, 2015

Solaredge Technologies (SEDG) began trading on the NASDAQ on 26 March 2015



Description

SolarEdge Technologies, Inc. (SolarEdge) is a provider of solar power harvesting and photovoltaic (PV) monitoring solutions. The Company's portfolio of products includes power optimizers, PV inverters and a Web portal for module-level monitoring and fault detection. Its SolarEdge power optimizer is a DC/DC converter which is connected by installers to each PV module or embedded by module manufacturers, replacing the solar junction box. Its SolarEdge DC-AC PV inverter works with the SolarEdge power optimizers. Its SolarEdge PV Monitoring Portal is a Web-based application that provides module-level, string-level and system-wide monitoring. The Company's customers include providers of solar PV systems to residential and commercial end users, such as SolarCity, SunRun Inc. and Vivint Solar, Inc.

Address

1 HaMada Street, Herziliya Pituach
HERZLIYA, 4673335
Israel
+972-9-9576620 (Phone)

Key stats and ratios

Q4 (Dec '14)2014
Net profit margin4.60%-16.05%
Operating margin5.78%-13.79%
EBITD margin--12.31%
Return on average assets10.68%-34.46%
Return on average equity--
Employees360
Founded in 2006, SolarEdge provides an intelligent inverter solution that has changed the way power is harvested and managed in photovoltaic systems. The SolarEdge DC optimized inverter system maximizes power generation at the individual solar module level while lowering the cost of energy produced by the PV system. SolarEdge's system consists of power optimizers, inverters and a cloud-based monitoring platform and addresses a broad range of solar market segments, from residential solar installations to commercial and small utility-scale solar installations. Since SolarEdge  began commercial shipments in 2010, they have shipped approximately 1.3 gigawatts of DC optimized inverter systems and the SolarEdge products have been installed in solar systems in 73 countries.

"SolarEdge is dedicated to transforming the world by making clean energy affordable through its solutions," said Nelson Griggs, Executive Vice President of Listing Services at Nasdaq. "We are pleased to add another ground-breaking clean energy technology company to the Nasdaq family and we are excited to celebrate more milestones with SolarEdge in the future."

By listing with Nasdaq, SolarEdge Technologies joins many of the world's largest and most revolutionary companies.  Nasdaq has been the exchange of choice to over 70 percent of technology companies listed in the U.S. markets.

Monday, January 5, 2015

Neuroderm (NDRM) began trading on the NASDAQ on 14 November 2014


Description

Neuroderm Ltd. is a clinical-stage pharmaceutical company. The Company is engaged in the development of treatments for central nervous system (CNS) disorders. It develops product candidates for the treatment of Parkinson’s disease and cognition. The Company’s product pipeline includes ND0612L, for moderate PD; ND0612H, for severe PD; ND0680, for severe PD; ND0701, for severe PD, and ND0801, for Cognitive Disorders. It developed a liquid formulation of levodopa (LD) and carbidopa (CD). The Company developed a line of LD/CD product candidates administered through a patch-pump or small belt pump that deliver a continuous, controlled dose of LD/CD to the blood stream. Its LD/CD line of product candidates includes ND0612L, ND0612H and ND0680. The Company also develops ND0701, a formulation of continuous apomorphine therapy for the treatment of Parkinson’s disease.

Address

3 Pekeris Street, Ruhrberg Science Bldg. Rabin Science Park Bell Entrance
REHOVOT, 7670212
Israel

Key stats and ratios

Q2 (Jun '14)2013
Net profit margin--
Operating margin--
EBITD margin--
Return on average assets-245.61%-2977.32%
Return on average equity--
Employees21

Thursday, September 25, 2014

Cyberark Software (CYBR) began trading on the NASDAQ on 24 September 2014

  • Shares of CyberArk Software(Nasdaq: CYBR), a Newton-based firm providing IT security from internal threats for the likes of Pfizer (NYSE: PFE) and British Telecom, raised $92.5 million in its initial public offering.
  • The company said it generated $66.2 million in revenue and profit of $6.6 million during 2013. CyberArk said as of March 31, it had 1,500 customers, including over 30 percent of the Fortune 100 and approximately 15 percent of the Global 2000.
  • Founded in 1999 in Israel, CyberArk has had its U.S. headquarters in Massachusetts since 2000. The firm now employs 364 overall and 114 in the U.S., with most of the U.S. employees in Newton. The company has additional sales offices in England, France, Germany and Singapore.
  • Profiting from the IPO was the firm’s largest shareholder, Israel-based Jerusalem Venture Partners, which owned 46.8 percent of the company prior to the offering. Other shareholders include: Goldman Sachs Group (24.1 percent) and Vertex Venture Capital (11.6 percent).
  • According to a 2012 report by market research firm IDC, worldwide spending on data center security solutions was $10.7 billion in 2011 and is expected to grow to $16.5 billion by 2016,





CyberArk Software's president and CEO, Udi Mokady.

Description
Cyberark Software Ltd is an Israel-based security company. The Company’s provides information technology security solutions that protect organizations from cyber attacks. The Company’s products include CyberArk Shared Technology Platform, Privileged Account Security Solution and Sensitive Information Management Solution. It offers Privileged Account Security Solution, a solution to protect, monitor, detect, alert, and respond to privileged accounts. The company also provides Enterprise Class Integration for devices, networks, applications, and servers. It’s CyberArk Privileged Session Manager that isolates, controls, and monitors privileged user access and activities. It’s CyberArk Sensitive Information Management Solution, a platform for sharing and distributing information to users across systems using Web, desktop, mobile, and email.

Address

94 Em-Ha'moshavot Road Park Azorim, P.O. Box 3143
PETAH TIKVA, 4970602
Israel

Website 

www.cyberark.com

Key stats and ratios

Q2 (Jun '14)2013
Net profit margin5.76%10.03%
Operating margin14.38%13.72%
EBITD margin-14.44%
Return on average assets5.11%8.61%
Return on average equity-0.63%4.17%
Employees387

Wednesday, September 17, 2014

Rewalk Robotics (RWLK) began trading on the NASDAQ on 12 September 2014






Description

Rewalk Robotics Ltd is an Israel-based medical device company. The Company is engaged in designing, developing and commercializing exoskeletons that allow wheelchair-bound individuals with mobility impairments or other medical conditions the ability to stand and walk once again. The Company has developed and is continuing to commercialize ReWalk, an exoskeleton that uses its patented tilt-sensor technology and an on-board computer and motion sensors to drive motorized legs that power movement. The Company offers two ReWalk products: ReWalk Personal and ReWalk Rehabilitation. ReWalk is a product that can fundamentally change the health and life experiences of users. ReWalk controls movement using subtle changes in the user’s center of gravity.

Address

Kochav Yokneam Building, Floor 6, PO Box 161
YOKNEAM, 2069200
Israel

Key stats and ratios

Q2 (Jun '14)2013
Net profit margin-938.00%-766.81%
Operating margin-763.80%-550.69%
EBITD margin--544.90%
Return on average assets-278.55%-185.16%
Return on average equity--822.10%
Employees63

Saturday, August 30, 2014

Israeli IPOs

Mobileye NV (MBLY), the technology company that went public a month ago, led gains among U.S.-listed Israeli stocks in August as investors shrugged off concern that the seven-week Gaza conflict will weaken the economy.

Mobileye has surged 73 percent to $43.22 since listing in New York on July 31, the biggest rally among all companies globally that raised $500 million or more in the past three months. Caesarstone Sdot-Yam Ltd. (CSTE), the maker of quartz counter-tops, climbed 20 percent in August, the second-best performance on the Bloomberg Israel-U.S. Equity Index, which rose 4.8 percent.

While signs have emerged that the Gaza fighting is starting to curb output at some Israeli businesses, hurt tourism and cut into consumer spending, investors have shown little concern, instead bidding up stocks in line with gains being posted in the U.S. and other major global markets. The performance of Mobileye and Caesarstone, which has more than tripled since its 2012 listing, could help bolster demand for more Israeli initial public offerings, according to Josef Schuster, the founder of Chicago-based IPOX Schuster LLC.

Record IPO

Mobileye’s $1 billion IPO was the biggest in the U.S. by an Israeli company on record, part of a rush of deals last month. Six Israeli companies have gone public in the U.S. this year, according to data compiled by Bloomberg. Eight more have offerings pending.

“We’re continuing to see moderate appetite for IPOs in the U.S. by Israeli companies,” Phyllis Korff, a lawyer at Skadden Arps, Slate, Meagher & Flop LLP in New York, said in an e-mail. “This activity could continue through the end of 2014 and into the first quarter of 2015,” said Korff, who worked on the Mobileye offering.

The Jerusalem-based technology company, whose customers include luxury electric-carmaker Tesla Motors Inc., posted 2013 net income of $19.9 million following two years of losses, according to its IPO prospectus. Revenue in 2013 was $81.2 million, more than double the figure from 2012.

Rate Cut
While global financial markets have shrugged off fighting in Gaza, it has begun to take its toll on Israel’s economy. The Bank of Israel unexpectedly cut interest rates to a record low on Aug. 25 in an attempt to boost an economy already hit by slowing exports.

Israeli growth slowed in the second quarter to 1.7 percent from 2.8 percent in the previous three months, as exports, which account for about a third of the economy, tumbled 18 percent, according to official data released Aug. 17.

The local TA-25 index rose 0.9 percent this month, trailing the 4.8 percent gain on the Bloomberg Israel-US Index. Tel Aviv stocks have appreciated 5.6 percent this year, compared with an 11 percent advance for U.S.-listed Israeli stocks.

Caesarstone (CSTE), which makes quartz kitchen counter-tops, surged this month after issuing a new full-year sales estimate that surpassed analysts’ projections. The stock has appreciated 373 percent since its IPO in March of 2012.

Friday, August 1, 2014

Mobileye (MBLY) began trading on the NYSE on 1 August 2014


Chairman & CTO, Amnon Shashua, President & CEO, Ziv Aviram and other members of Mobileye’s leadership team ring the Opening Bell at The New York Stock Exchange on August 1, 2014 in New York City





Here are four things to know about the company:
Financials: The company has a long record of losing money. Revenue in 2013 doubled to $81.2 million, from $40.3 million. While Mobileye posted a $19.9 million profit for 2013, it posted a $19.6 million loss for the first quarter of 2014. In its prospectus, it noted there is no assurance that it will become and remain profitable.
Indeed, it forecasts a bottom line for the second quarter of between a loss of $0.1 million and a profit of $0.6 million, compared with a profit of $4.0 million for the quarter ended June 30, 2013.
In addition, it flagged a “material weakness in our internal control over financial reporting, which resulted in the restatement of our 2013 earnings per share.”
Customers: General Motors Corp. is its biggest client, accounting for 29% of revenue from original equipment manufacturing. Honda accounts for 25% of OEM revenue, followed by BMW at 15%, it said. OEM revenue totaled $63.3 million in 2013, or 78% of total revenue.
Who cashed out through the IPO: Most of the shares sold came from existing investors. The biggest is a unit of Goldman Sachs Group Inc., which sold 4.4 million shares, reducing its stake to 12.3% from 14.9%. Other sellers included Amnon Shashua and Ziv Aviram, the company’s founders and senior executives.
Political risk: Mobileye noted this in its prospectus:
“We could be harmed by any major hostilities involving Israel, the interruption or curtailment of trade between Israel and its trading partners or a significant downturn in the economic or financial condition of Israel.
“Some of our employees in Israel are obligated to perform annual reserve duty in the Israeli military and are subject to being called for additional active duty under emergency circumstances.”

Thursday, June 19, 2014

Lumenis (LMNS) began trading on the NASDAQ on 27 February 2014


Lumenis Ltd. is a provider of energy-based, minimally invasive clinical solutions. The Company operated in three segments: surgical, ophthalmic and aesthetic. It provides energy-based solutions for both medically necessary and elective procedures, primarily for the aging population. Its focused product offerings provide solutions for a range of minimally invasive procedures. Its solutions include its VersaPulse PowerSuite platform using high-powered holmium lasers for urologic applications, its M22 multi-energy, multi-application platform for the treatment of various skin conditions, and its Selecta multi-modality platform for retinal, secondary cataract and glaucoma therapies. Its primary target markets for its products are hospitals, outpatient clinics, ambulatory surgery centers, physicians’ offices, private clinics and aesthetic chains.

Address

6 Hakidma Street Yokneam Industrial Park, P.O.B. 240
YOKNEAM, 2069204
Israel

Website links 

http://www.lumenis.com

Key stats and ratios

Q4 (Dec '13)2013
Net profit margin6.61%6.55%
Operating margin8.86%9.65%
EBITD margin-9.36%
Return on average assets9.31%8.88%
Return on average equity123.60%198.75%
Employees1,061

Wednesday, June 11, 2014

Galmed (GLMD) began trading on the NASDAQ on 13 March 2014


Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugates (FABACs). Its product candidate, aramchol, has the potential to be a disease modifying treatment for fatty liver disorders, specifically Non-Alcoholic Steato-hepatitis (NASH), which constitutes an unmet medical need. The Company has completed three clinical trials of aramchol. The Company focuses on providing a multi-center, double-blind, randomized Phase IIb placebo-controlled clinical trial of aramchol in NASH patients who also suffer from obesity and insulin resistance.

The company was founded in 2000 and is headquartered in Tel Aviv, Israel. 


Address

AMOT HAMISHPAT BLDG. 8 SHAUL HAMELECH BLVD.
TEL AVIV-YAFO, 6473307
Israel

Key stats and ratios

Q1 (Mar '14)2013
Net profit margin--
Operating margin--
EBITD margin--
Return on average assets--3768.32%
Return on average equity--
Employees5

Sunday, March 30, 2014

MediWound (MDWD) began trading on the NASDAQ on 20 March 2014


Description

MediWound Ltd. is a fully integrated biopharmaceutical company. The Company is focused on developing, manufacturing and commercializing products to address unmet needs in the fields of severe burns, chronic and other hard-to-heal wounds and connective tissue disorders. The Company’s biopharmaceutical product, NexoBrid, which is based on its patented proteolytic enzyme technology, represents a new paradigm in burn care management, and its clinical trials have demonstrated, with statistical significance, its ability to non-surgically and rapidly remove the eschar earlier upon patient admission, without harming viable tissues. The Company launched NexoBrid in December 2013 in the European Union through its wholly-owned German subsidiary, targeting a focused audience of burn specialists treating patients in burn centers and hospital burn units.

Address

42 Hayarkon Street, Industrial Zone
YAVNE, ZF 8122745
Israel

Friday, March 21, 2014

Borderfree (BRDR) began trading on the NASDAQ on 21 March 2014

  • Update (May 6, 2015) : Borderfree (BRDR) was acquired by Pitney Bowes (PBI) for for $14.00 per share or $395 million in 2015.
--------

Borderfree Inc. (Nasdaq: BRDR) raised a gross $80 million in an issue of five million shares at $16 per share - the upper end of its offer - at a company value of $488 million, after money. The share price rose 25% in its first day of trading on Friday to $20, giving a market cap of $610 million.



Borderfree was founded in 1999 by Yuval Tal in Israel under the name FiftyOne, as a forex conversion site for retailers. It subsequently expanded its business to become the leader in its field, offering worldwide e-commerce for American retailers. The company is now incorporated in the US and headquartered in New York City, and keeps one of its two R&D centers in Israel. The company has 49 R&D employees, but does not disclose how many are in Israel. Altogether, it has 189 employees.


The IPO's biggest beneficiaries are Borderfree's investors, beginning with Pitango Venture Capital. The IPO reduced its stake in the company from 32.8% to 27.4%, worth $167 million. In second place is Adam Street Partners, which saw its stake narrow to 18.1%, worth $110.5 million.

Thursday, March 6, 2014

Kamada (KMDA) began trading on the NASDAQ on 31 May 2013


Description

Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy. Its product line also comprises Protosol to reduce blood loss in patients undergoing cardiac surgery; Heparin sodium injection for coagulation inhibition and prophylaxis of thromboembolic diseases and Heparin Lock Flush to maintain potency of intravenous injection device among other.

Address

7 Sapir St. Kiryat Weizmann Science Park, P.O Box 4081
NESS-ZIONA, 74140
Israel